Clinical Trial Detail

NCT ID NCT03428802
Title Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Rutgers, The State University of New Jersey
Indications

Advanced Solid Tumor

Therapies

Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST